Healthcare / Diagnostics & ResearchLSE
$2.16
+0.06 (+2.86%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-15.1M · quality 71.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$42M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-77.1%
↓Gross Margin
62.2%
↑Debt/Equity
0.23
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+41.4%
FCF CAGR
—
FCF margin
-485.4%
FCF / Net income
0.98x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.9M · net income $-14.2M · FCF $-13.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.9M | $2.9M | $2.2M | $1.0M | $1.0M |
| Net Income | $-14.2M | $-14.2M | $-20.1M | $-21.7M | $-15.0M |
| EBITDA | $-13.0M | $-13.0M | $-19.0M | $-21.2M | $-15.7M |
| EPS | -0.05 | -0.05 | -0.08 | -0.09 | -0.07 |
| Gross Margin | 62.2% | 62.2% | 69.9% | 58.9% | 70.2% |
| Operating Margin | -540.7% | -540.7% | -935.9% | -2508.1% | -1710.5% |
| Net Margin | -497.0% | -497.0% | -921.0% | -2083.2% | -1481.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.23 | 0.23 | 0.20 | 0.12 | 0.06 |
| Current Ratio | 3.13 | 3.13 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-13.9M | $-13.9M | $-15.1M | $-17.9M | $-15.8M |
| Returns | |||||
| ROE | -77.1% | -77.1% | -87.8% | -54.1% | -37.2% |
| Valuation | |||||
| P/B | 34.55 | 34.55 | 295.70 | 157.20 | 676.37 |
| Growth & Yield | |||||
| Revenue Growth | 30.9% | 30.9% | 110.0% | 2.8% | — |
| EPS Growth | 37.5% | 37.5% | 12.1% | -31.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-73.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.08 → -0.05
Residual
-73.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.